Terms: = Brain cancer AND PR, PGR, progesterone receptor AND Clinical Outcome
16 results:
1. PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
Weller J; Katzendobler S; Karschnia P; Lietke S; Egensperger R; Thon N; Weller M; Suchorska B; Tonn JC
J Neurooncol; 2021 Jun; 153(2):283-291. PubMed ID: 33932195
[TBL] [Abstract] [Full Text] [Related]
2. Tumor-dose-rate variations during robotic radiosurgery of oligo and multiple brain metastases.
Wilhelm ML; Chan MKH; Abel B; Cremers F; Siebert FA; Wurster S; Krug D; Wolff R; Dunst J; Hildebrandt G; Schweikard A; Rades D; Ernst F; Blanck O
Strahlenther Onkol; 2021 Jul; 197(7):581-591. PubMed ID: 32588102
[TBL] [Abstract] [Full Text] [Related]
3. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Steuer CE; Wu C; Lawson DH; Kudchadkar R; Master VA; El-Rayes B; Ramalingam SS; Owonikoko TK; Harvey RD
BMC Cancer; 2019 Aug; 19(1):857. PubMed ID: 31464611
[TBL] [Abstract] [Full Text] [Related]
4. Cost-effectiveness of preoperative motor mapping with navigated transcranial magnetic brain stimulation in patients with high-grade glioma.
Butenschön VM; Ille S; Sollmann N; Meyer B; Krieg SM
Neurosurg Focus; 2018 Jun; 44(6):E18. PubMed ID: 29852777
[TBL] [Abstract] [Full Text] [Related]
5. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract] [Full Text] [Related]
6. Dabrafenib Therapy in 30 Patients with Melanoma Metastatic to the brain: a Single-centre Controlled Retrospective Study in Hungary.
Gorka E; Fabó D; Gézsi A; Czirbesz K; Fedorcsák I; Liszkay G
Pathol Oncol Res; 2018 Apr; 24(2):401-406. PubMed ID: 28567600
[TBL] [Abstract] [Full Text] [Related]
7. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
[TBL] [Abstract] [Full Text] [Related]
8. Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.
Rao PS; Labhart M; Mayhew SL; Thirumala S; Rao US
Tumour Biol; 2014 Jul; 35(7):7267-73. PubMed ID: 24777335
[TBL] [Abstract] [Full Text] [Related]
9. clinical outcome of surgically treated low-grade gliomas: a retrospective analysis of a single institute.
Turkoglu E; Gurer B; Sanli AM; Dolgun H; Gurses L; Oral NA; Donmez T; Sekerci Z
Clin Neurol Neurosurg; 2013 Dec; 115(12):2508-13. PubMed ID: 24225484
[TBL] [Abstract] [Full Text] [Related]
10. Early assessment of radiation response using a novel functional imaging modality -- [18F]fluorocholine PET (FCH-PET): a pilot study.
Parashar B; Wernicke AG; Rice S; Osborne J; Singh P; Nori D; Vallabhajosula S; Goldsmith S; Chao KS
Discov Med; 2012 Jul; 14(74):13-20. PubMed ID: 22846199
[TBL] [Abstract] [Full Text] [Related]
11. The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement.
Racila E; Racila DM; Ritchie JM; Taylor C; Dahle C; Weiner GJ
Immunogenetics; 2006 Feb; 58(1):1-8. PubMed ID: 16465510
[TBL] [Abstract] [Full Text] [Related]
12. Meningioma: an update.
Lusis E; Gutmann DH
Curr Opin Neurol; 2004 Dec; 17(6):687-92. PubMed ID: 15542977
[TBL] [Abstract] [Full Text] [Related]
13. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
[TBL] [Abstract] [Full Text] [Related]
14. Apolipoprotein E polymorphism and breast carcinoma: correlation with cell proliferation indices and clinical outcome.
Zunarelli E; Nicoll JA; Migaldi M; Trentini GP
Breast Cancer Res Treat; 2000 Oct; 63(3):193-8. PubMed ID: 11110053
[TBL] [Abstract] [Full Text] [Related]
15. Prolactinomas in male and female patients: a comparative clinicopathologic study.
Calle-Rodrigue RD; Giannini C; Scheithauer BW; Lloyd RV; Wollan PC; Kovacs KT; Stefaneanu L; Ebright AB; Abboud CF; Davis DH
Mayo Clin Proc; 1998 Nov; 73(11):1046-52. PubMed ID: 9818037
[TBL] [Abstract] [Full Text] [Related]
16. Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features.
Brandis A; Mirzai S; Tatagiba M; Walter GF; Samii M; Ostertag H
Neurosurgery; 1993 Aug; 33(2):212-7; discussion 217-8. PubMed ID: 8367042
[TBL] [Abstract] [Full Text] [Related]
